Home » Topics » BioWorld Science

BioWorld Science
RSS

EMA approves Lynparza tablets for the treatment of platinum-sensitive relapsed ovarian cancer

May 9, 2018

FDA clears Palladio to begin phase II study of lixivaptan in ADPKD

May 9, 2018

CymaBay Therapeutics initiates phase IIb trial of seladelparin NASH

May 9, 2018

Bristol-Myers Squibb presents novel nuclear receptor ROR-gamma inverse agonists

May 9, 2018

Merck & Co. patents lysine-specific demethylase 5B inhibitors

May 9, 2018

New RIP-1 inhibitors discovered at Roche, Genentech

May 9, 2018

Intravenous formulation of Akynzeo launched in the U.S.

May 9, 2018

Cellcentric divulges new KAT3 and/or CREB-binding protein inhibitors

May 9, 2018

Nektar Therapeutics initiates phase Ib trial of NKTR-358 in patients with SLE

May 9, 2018

Novartis describes novel IKACh channel blockers

May 9, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...